TAPUR Study – FDA approved therapies Targeted therapies such as BRAF, CDK2NA, etc.

Omid Hamid MD
Chief, Translational Research/Immuno-Oncology
Director shares, TAPUR Study – FDA approved therapies Targeted therapies such as BRAF, CDK2NA, etc. at the 2018 Oncology Summit in Huntington Beach, CA

Go to: http://www.moasc.org for more information